SEC Form 4 · accession 0001140361-17-019306
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Mueller
Officer — SVP, Corporate Controller
Period of report
Apr 28, 2017
Accepted (ET)
May 10, 2017 · 3:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 28, 2017 | A | 270 | $70.304 | A | 18,350 | D | |
| Common StockF2,F3 | May 8, 2017 | S | 4,882 | $91.17 | D | 13,468 | D | |
| Common StockF2 | May 8, 2017 | M | 2,600 | $21.51 | A | 16,068 | D | |
| Common StockF2,F3 | May 8, 2017 | S | 2,600 | $93.17 | D | 13,468 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F2,F4 | $21.51 | May 8, 2017 | M | 2,600 | D | Nov 12, 2010 | May 11, 2020 | Common Stock | 2,600 | 2,671 | D |
Explanation of responses
- F1Represents shares acquired by the reporting person on April 28, 2017, pursuant to the issuer's Employee Stock Purchase Plan.
- F2Trade made pursuant to a 10b5-1 plan executed on March 13, 2017.
- F3All shares were sold at the same price.
- F4Option grant vests 12/48th on March 22, 2018 and 1/48th on the 22nd day of each month thereafter.